Porphyrin Cholesterol Conjugates for Enhanced Photodynamic Immunotherapy toward Lung Cancer

Lung Cancer is the major cause of Cancer death worldwide. Immune checkpoint inhibitors (ICIs) of PD-1/PD-L1 have improved the survival rate in some patients with lung Cancer. However, the efficacy of ICIs is limited by the inhibitory tumor immune microenvironment. Herein, we designed porphyrin Cholesterol conjugates (TPPC) for synergistic photodynamic therapy (PDT)-immunotherapy for lung Cancer. Porphyrin derivatives with great Reactive Oxygen Species (ROS) production efficiency have been applied as photosensitizers in clinics, and Cholesterol is one of the main components of the cell membrane. Porphyrin Cholesterol conjugates could assemble into nanoparticles (NPs) in the absence of surfactants or amphiphilic Polymers. On the other hand, TPPC NP-mediated PDT could accumulate at the tumor site and induce immunogenic cell death to stimulate and recruit antigen-presenting cells to mature and activate T cells, rendering Cancer cells more sensitive to ICIs. Importantly, the combination strategy reshapes the tumor immune microenvironment to enhance the antitumor immune response and significantly suppresses the tumor growth and eliminates metastasis. This study offers theoretical guidance for the combination of PDT and ICIs as a potential therapeutic option in lung Cancer.

cholesterol; immunogenic cell death; photodynamic therapy; porphyrin; self-assembly.